Centro de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS)
Centro singular
![Foto de Centro de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS)](/img/noimage.png)
![Foto de Hospital Ramón y Cajal](/img/noimage_org.png)
Hospital Ramón y Cajal
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Ramón y Cajal (52)
2024
-
An Insertion Within SIRPβ1 Shows a Dual Effect Over Alzheimer's Disease Cognitive Decline Altering the Microglial Response
Journal of Alzheimer's Disease, Vol. 98, Núm. 2, pp. 601-618
-
Colchicine in acute heart failure: Rationale and design of a randomized double-blind placebo-controlled trial (COLICA)
European Journal of Heart Failure
-
Evaluation of Genetic Variants Associated with the Risk of Thiopurine-Related Pancreatitis: A Case Control Study from ENEIDA Registry
Digestive Diseases, Vol. 42, Núm. 3, pp. 257-264
-
Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study
European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 421-433
-
Meta-analysis of genome-wide association studies for cancer therapy-related cardiovascular dysfunction and functional mapping highlight an intergenic region close to TP63
Scientific Reports, Vol. 14, Núm. 1
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Erratum: Author Correction: Common variants in Alzheimer's disease and risk stratification by polygenic risk scores (Nature communications (2021) 12 1 (3417))
Nature communications
-
Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study
European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360
-
Mendelian Randomisation Confirms the Role of Y-Chromosome Loss in Alzheimer’s Disease Aetiopathogenesis in Men
International Journal of Molecular Sciences, Vol. 24, Núm. 2
-
Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
Patient Preference and Adherence, Vol. 17, pp. 839-849
2022
-
Challenges in managing patients with heart failure with reduced ejection fraction
Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 1-7
-
Metabolic-associated fatty liver disease: From simple steatosis toward liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, organized by the Spanish Association for the Study of the Liver (AEEH)
Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 724-734
-
New insights into the genetic etiology of Alzheimer's disease and related dementias
Nature genetics, Vol. 54, Núm. 4, pp. 412-436
-
Role of vericiguat in the overall etiopathogenesis of heart failure with reduced ejection fraction. Current position
Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 8-14
-
Therapeutic approach to patients with heart failure with reduced ejection fraction. The role of vericiguat
Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 23-29
-
Vericiguat in heart failure: from scientific evidence to clinical practice
Revista Clinica Espanola
-
Vericiguat: VICTORIA trial results
Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 15-22
2021
-
A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure
Frontiers in Physiology, Vol. 12
-
Common variants in Alzheimer's disease and risk stratification by polygenic risk scores
Nature communications, Vol. 12, Núm. 1, pp. 3417
-
Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events
Journal of cardiovascular pharmacology, Vol. 77, Núm. 2, pp. 164-169